Published in Clin Exp Metastasis on July 05, 2016
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin Oncol (2017) 0.75
The prognostic significance of DAPK1 in bladder cancer. PLoS One (2017) 0.75
Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin. Sci Rep (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
The B7 family revisited. Annu Rev Immunol (2005) 13.51
T cell exhaustion. Nat Immunol (2011) 11.08
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev (2015) 11.05
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 7.49
Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol (2010) 7.11
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol (2005) 6.38
Cancer immunology. N Engl J Med (2008) 5.22
EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol (2013) 4.58
Epidemiology and risk factors of urothelial bladder cancer. Eur Urol (2012) 4.45
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity (1996) 2.74
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res (2012) 2.68
Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology (2004) 2.64
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood (2004) 2.33
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol (2015) 1.90
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother (2006) 1.81
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol (2015) 1.74
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol (2015) 1.73
Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol (2002) 1.71
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol (2009) 1.40
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol (2015) 1.21
Links between innate immunity and normal tissue radiobiology. Radiat Res (2010) 1.19
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med (2015) 1.18
Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol (2013) 1.16
Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression. Front Immunol (2014) 1.07
Crosstalk between T lymphocytes and dendritic cells. Crit Rev Immunol (2012) 1.07
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. Cancer Res (2015) 0.98
Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res (2014) 0.94
New therapeutic challenges in advanced bladder cancer. Semin Oncol (2012) 0.93
Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology (2012) 0.93
Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy. Curr Cancer Ther Rev (2006) 0.92
The role of inflammation in bladder cancer. Adv Exp Med Biol (2014) 0.91
Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma. Br J Cancer (2010) 0.87
Association between the cytotoxic T-lymphocyte antigen 4 +49A/G polymorphism and bladder cancer risk. Tumour Biol (2013) 0.80
Tumor immune escape mechanisms that operate during metastasis. Curr Pharm Biotechnol (2011) 0.80
Checkpoint inhibitors in bladder and renal cancers: results and perspectives. Immunotherapy (2015) 0.80
Radiation in combination with immune-checkpoint inhibitors. Lancet Oncol (2015) 0.76
Emerging Immunotargets in Bladder Cancer. Curr Drug Targets (2016) 0.75
Systemic anti-CTLA-4 and intravesical Bacille-Calmette-Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism? Med Hypotheses (2016) 0.75
Preliminary results of an immunotherapy trial on terminal leukaemic lymphosarcoma. Biomedicine (1975) 0.75
Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors? Curr Urol Rep (2015) 0.75